GOVERNMENT OF WESTERN AUSTRALIA

PathWest LABORATORY MEDICINE WA

PathWest Molecular Anatomical Pathology

Community Health and Hospital Programme (CHHP)

Information Sheet

GOVERNMENT OF WESTERN AUSTRALIA

PathWest LABORATORY MEDICINE WA

About

The CHHP programme commenced at PathWest Molecular Anatomical Pathology (AP) on the 1st of July 2020. Federal funding was received by PathWest Molecular AP, providing opportunity for WA cancer patients access to comprehensive genomic profiling (NGS), using state of the art Massively Parallel Sequencing technology.

- Comprehensive genomic profiling provides biomarker information to refine diagnosis and prognosis and to align patients with the most suitable treatment strategy according to their individual tumour molecular profile. This has been particularly beneficial for patients for whom conventional treatment options have been exhausted.
- The programme has enabled the discipline to establish streamlined testing pathways across the major public and private hospitals and regional centres.

Who can participate?

Patients with a diagnosis of cancer for whom the treating doctor deems comprehensive genomic profiling (NGS) will assist in the management of the patient.

How do I refer my patient to the CHHP Programme?

Complete the CHHP consent form, along with the patient and the Clinical information Sheet (to aid with Molecular Tumour Board discussions). Email both forms, and the pathology report of the specimen to be tested, to the Molecular AP Pathwest QEIIMC inbox; QEmoleculararap.Pathwest@health.wa.gov.au

What type of material is required?

Tissue samples collected as part of routine patient care (such as tissue resections, diagnostic biopsies, core needle biopsies or fine needle aspirations (guided by CT, EBUS or EUS)).
To proceed with comprehensive NGS, we require a FFPE block of representative tumour material.

How long until I receive my patients results?

Generally, comprehensive NGS results are returned to the patient's oncologist within 4-6 weeks.

Molecular Tumour Board Meetings

Molecular Pathologists, Oncologists and Molecular Scientists meet weekly at our molecular multidisciplinary team meetings, called Molecular Tumour Board (MTB) meetings, to assess the NGS data for its clinical benefit.
At this meeting, the members will discuss the best treatment strategy based on the patients NGS data and will provided a recommendation considering the results and the latest medical findings.

Outcomes

Comprehensive molecular profiling of cancer biomarkers has enabled more informed therapeutic strategies, potentially improving patient care and treatment outcomes.
Through the CHHP Programme, PathWest Molecular Anatomical Pathology has successfully identified biomarkers that have led to new treatment strategies and enrolment in clinical trials.
The CHHP Programme has also identified biomarkers that predict response or resistance to approved therapies, as well as primary and additional actionable targets.

Molecular Tumour Board

How To Attend

Meetings are held at 4.30pm every Monday, excluding Public Holidays. A calendar invite is circulated to all Molecular Tumour Board Members. There is a Microsoft Teams link embedded within the calendar invite, or alternatively clinicians are encouraged to attend in person to the PathWest AP Seminar Room, J-block ground floor, QEII Medical Centre.

A list of patients to be discussed is sent out via email each Friday before the meeting. The reports are circulated on the following Monday.

To attend a Molecular Tumour Board meeting please contact:
PathWestOfficeoftheAPServiceDirector@health.wa.gov.au or telephone 08 6457 1862.

Participating Sites

- Sir Charles Gairdner Hospital
- King Edward Memorial Hospital
- Perth Children's Hospital
- Fiona Stanley Hospital
- Royal Perth Hospital
- Hollywood Private Hospital
- Joondalup Health Campus
- Peel Health Campus
- St John of God Bunbury
- St John of God Murdoch
- St John of God Midland (public and private)
- St John of God Subiaco
- Albany Health Campus

Contacts

- Molecular AP Pathwest QEIIMC General Inbox; *QEmoleculararap.Pathwest@health.wa.gov.au*
- Marisa Fewster, Clinical Project Coordinator: marisa.fewster@health.wa.gov.au
- Chief Principal Investigator, Clinical Professor Benhur Amanuel; *pathwest.officeoftheapservicedirector@health.wa.gov.au*
- Principal Investigator, Dr Cleo Robinson; *cleo.robinson@health.ea.gov.au*